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BACKGROUND: Themanagementof pediatricmelanoma (PM) has largely been extrapolated fromadult data. However, the behaviorof PM
appearstodifferfromitsadultcounterparts.Therefore,aninternationalPMregistrywascreatedandanalyzed.METHODS: Twelve institutions
contributed deidentified clinicopathologic and outcome data for patients diagnosed with PM from 1953 through 2008. RESULTS:
Overall survival (OS) data were reported for 365 patients with invasive PM who had adequate follow-up data. The mean age of the
patients was 16 years (range 1 year-21 years). The 10-year OS rate, 80.6%, tended to vary by patient age: 100% for those aged birth to
10 years, 69.7% for those aged > 10 years to 15 years, and 79.5% for those aged > 15 years to 20 years (P5.147). Patients with melano-
mas measuring  1 mm had a favorable prognosis (10-year OS rate of 97%), whereas survival was lower but similar for patients with
melanomas measuring > 1 mm to 2 mm, >2 mm to 4 mm, and >4 mm (70%, 78%, and 80%, respectively; P5.0077). Ulceration and
lymph node metastasis were found to be correlated with worse survival (P5.022 and P5.017, respectively). The 10-year OS rate was
94.1% for patients with American Joint Committee on Cancer stage I disease, 79.6% for those with stage II disease, and 77.1% for
patients with stage III disease (P<.001). CONCLUSIONS: Tumor thickness, ulceration, lymph node status, and stage were found to be
significant predictors of survival in patients with PM, similar to adult melanoma. There is a trend toward increased survival in children
aged  10 years versus adolescents aged > 10 years. Further analyses are needed to probe for potential biological and behavioral dif-
ferences in pediatric versus adult melanoma. Cancer 2013;119:4012-9. VC 2013 American Cancer Society.
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INTRODUCTION
Although pediatric melanoma (PM) is rare (occurring in approximately 1%-4% of melanomas), its incidence reportedly
increased 46% from 1973 to 2001.1 Despite its low incidence (approximately 450 new patients aged < 20 years are
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diagnosed each year in the United States), melanoma is
the most common solid tumor in those aged 15 years to
29 years.2,3 The rarity of PM and the challenge in differ-
entiating PMs from pigmented atypical melanocytic neo-
plasms (PAMNs) can cause management delays, anxiety
related to an uncertain diagnosis, and less-than-ideal out-
comes.1,4-6 Recently, the expanding array of therapeutic
options for patients with melanoma has provided an addi-
tional incentive to understand the behavior of PM.
The biology of nominally similar pathological
lesions in pediatric and adult populations appears to dif-
fer.7,8 A variety of retrospective databases and clinical
case reports, often based on single-institution experien-
ces, have reported on PM, with varying results. Data are
conflicting regarding the relative contributions of patient
sex1,9-13 and lesion location.1,9,11 A variety of risk factors
have also been examined. For example, inactivating
mutations in the CDKN2A gene (encoding p16 and
p14ARF) appear less common in patients with PM than
in those with familial melanoma or in individuals with
multiple primary melanomas.14,15 Many studies used age
cutoff values (aged 10 years-15 years) as a proxy for pre-
pubertal versus postpubertal melanoma. The larger,
institutional-based, and population-based studies have
demonstrated a higher prevalence of melanoma and
decreased survival in adolescents versus children,5,7,14-18
but this is not the case in all studies.8,19
Melanomas in children frequently are diagnosed as
having thicker Breslow depths than in adults. Some stud-
ies have demonstrated that thicker lesions are associated
with decreased overall survival (OS), whereas others do
not.19-21 Moreover, although some investigators have
found survival outcomes are more favorable in younger
patients than in adults with lesions of similar thickness,9
others suggest that, when controlled for thickness and sen-
tinel lymph node (SLN) status, survival outcomes for chil-
dren and adults are similar.22 Although PM has been
reported to frequently metastasize to lymph nodes, the
prognostic implications of such metastases require further
clarification.9,23,24
Given the conflicting data in the literature from
mostly small, single-center studies, we established an
international registry in January 2006 to study the clinical
behavior of PMs in a multicenter setting. We sought to
identify prognostic factors associated with survival out-
comes in patients with PM.
MATERIALS AND METHODS
Institutional Review Board approval was obtained at the
12 participating institutions for enrollment in the registry.
An Excel spreadsheet=SQL (Structured Query Language)
database was developed for Web entry of deidentified de-
mographic and pathologic data for patients with PM who
were aged  20 years. Patients were grouped into those
aged 10 years and those aged> 10 years but 20 years
as well as into 5-year age brackets. In addition, a group of
34 patients aged > 20 years to 23 years was entered into
the database and retained for comparison, as recom-
mended by our statisticians. The data were locked on Oc-
tober 31, 2008.
Pathologic, surgical, and follow-up data were col-
lected for all lesions. For the category of mitosis, we used
binary categorization (yes vs no, based on the presence of
at least 1 mitosis per high-power field or per mm2), allow-
ing outcomes from heterogeneous reports over the
extended registry time frame as pathological evaluation
methods changed over time. Central pathology review
was not feasible for this initial effort. All staging was based
on the sixth edition of the American Joint Committee on
Cancer (AJCC) cancer staging manual because the data
were planned for evaluation using this edition.25
Statistical Analysis
Differences in lesion frequency and specific descriptive in-
formation were compared using the chi-square test. The
Kaplan-Meier method was used to generate survival
curves, followed by univariate analysis for prognostic fac-
tors using linear trends and log-rank tests. Because the
log-rank test compares the actual distribution of OS,
younger patients potentially could have a better survival
distribution by virtue of their age at the time of the mela-
noma diagnosis. A post hoc analysis employing the Fisher
exact test was also used to evaluate survival outcomes and
confirm the results of the log-rank test. We evaluated
patients with 5 years and 10 years of follow-up and labeled
them as dead or alive during the specified follow-up.
For nonsurvival outcomes, patients with in situ mel-
anoma and invasive melanoma for whom there were no
missing data elements were considered evaluable for each
factor being investigated. For OS, only patients with inva-
sive melanoma were considered. For analysis of disease-
free survival (DFS), patients with stage IV disease at the
time of diagnosis were further excluded.
RESULTS
Table 1 shows the distribution of PM by patient age. The
majority of the lesions were invasive melanoma, and the
largest percentage of cases occurred in patients aged > 15
years to 20 years. There were 415 patients with invasive
melanoma, but not all had complete data elements. The
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32 patients with in situ melanoma were excluded from
subsequent survival analysis, leaving a total of 365 patients
with melanoma who were evaluable, with the years of di-
agnosis ranging from 1953 to 2008. The mean age of the
patients was 16 years (standard deviation, 3.6 years)
(range, 1 year-21 years). DFS was only analyzed for 351
patients with PM (excluding 14 patients with stage IV
disease).
Table 2 shows the characteristics of the patients with
evaluable invasive melanoma stratified by age. Females
predominated overall, as well as in the group aged > 10
years; males predominated among those aged  10 years.
Mean thickness was significantly higher in children aged
 10 years compared with those aged > 10 years and
 20 years (2.66 mm vs 1.59 mm; P5 .0041). There was
a trend toward more mitoses in the younger age range
compared with the other groups, although a large percent-
age of the cases were missing information. The majority
of the lesions were not ulcerated. More ulceration was
found in children aged  10 years of age compared with
those aged> 10 years.
The positivity rate for SLN biopsy (SLNB) was
30%, noted in 55 of the 183 patients who underwent bi-
opsy (of the 365 patients with invasive PM). The majority
of SLNB-positive patients (41 patients; 75%) had only 1
SLNB-positive lymph node; 13 had 2 positive lymph
nodes and 1 had 5 positive lymph nodes; 128 patients had
no positive lymph nodes. Final lymph node and overall
staging is shown in Table 3. The majority of patients
(53.7%) presented with stage I disease. Furthermore,
younger patients (those aged  10 years) were found to
have higher-stage disease than the older cohorts
(P5 .0054).
OS data for patients with PM are shown in Table 4.
The 10-year OS rate was 80.6%. Differences in OS across
age groups were not found to be statistically significant
(P5 .1473, log-rank test). When the groups were con-
densed, the 10-year OS rate in those aged  10 years was
not significantly different from that of patients aged > 10
years using either the log-rank test (P5 .0856) or the
Fisher exact test (P5 .5019), even when those individuals
aged > 20 years were removed. The 5-year OS rate for
patients aged  10 years was 100% (16 of 16 patients)





>10 Years to 20 Years
Patients Aged
>20 Years
Year of diagnosis Median 2000 2001 2004 1999
(Range) 1953-2008 1976-2007 1953-2008 1983-2006
Sex, no. Female 210 (57.5%) 9 (36.0%) 185 (57.8%) 16 (80.0%)
Male 155 (42.5%) 16 (64.0%) 135 (42.2%) 4 (20.0%)
P 5 .04
Thickness Mean (SD) 1.63 (1.94) 2.66 (2.06) 1.59 (1.96) 1.04 (0.72)
P 5 .0041
Clark level I 3 (1.0%) 1 (6.3%) 2 (0.7%) 0 (0.0%)
II 50 (16.2%) 1 (6.3%) 43 (15.6%) 6 (35.3%)
III 79 (25.7%) 1 (6.3%) 77 (28.0%) 1 (5.9%)
IV 159 (51.6%) 8 (50.0%) 141 (51.3%) 10 (58.8%)
V 17 (5.5%) 5 (31.3%) 12 (4.4%) 0 (0.0%)
Unknown 57 9 45 3
P 5 .0001
Mitosis No 122 (52.1%) 6 (40.0%) 104 (51.7%) 12 (66.7%)
Yes 112 (47.9%) 9 (60.0%) 97 (48.3%) 6 (33.3%)
Unknown 131 10 119 2
P 5 NS
Ulceration No 265 (87.8%) 19 (79.2%) 229 (88.4%) 17 (89.5%)
Yes 37 (12.3%) 5 (20.8%) 30 (11.6%) 2 (10.5%)
Unknown 63 1 61 1
P 5 NS
Abbreviations: NS, not significant; SD, standard deviation.
TABLE 1. Distribution of Melanomas by Age
Entire Patient










5 0 8 0 6
>5 to 10 4 21 2 19
>10 to 15 12 107 10 98
>15 to 20 21 252 19 222
>20 2 27 1 20
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versus 81% (90 of 111 patients) for those aged> 10 years
but was not statistically significantly different (P5 .3572,
Fisher exact test). The median follow-up was 3 years
(range, 0.02 years-31 years). It is interesting to note that
the survival analysis only included patients who had at
least 5 years to 10 years of follow-up; few patients had
 10 years of follow-up.
Other potential prognostic factors were analyzed for
their impact on OS (Table 4). OS did not appear to differ
by sex. Primary melanoma thickness was found to be sig-
nificantly correlated with OS. OS was similar for all thick-
nesses of primary melanomas measuring > 1 mm (Table
4) (Fig. 1 Top). The presence of primary tumor ulceration
also was found to be significantly correlated with OS
(P5 .0022) (Fig. 1 Middle). The presence or absence of
mitoses did not appear to be correlated with OS. A posi-
tive lymph node dissection in the absence of SLNB was
correlated with worse OS. Disease stage was found to be
highly significant in predicting OS for patients with PM
(Fig. 1 Bottom).
The 5-year and 10-year DFS rates were 79.7% and
71.5%, respectively, for the evaluable melanoma patients.
As expected, DFS decreased with stage of disease: a 10-
year DFS rate of 83.05% for patients with stage I disease,
a 66.74% DFS rate for those with stage II disease, and a
63.30% DFS rate for patients with stage III disease
(P5 .0046, log-rank test). DFS did not appear to differ
based on age, mitoses, sex, lymph node status, or ulcera-
tion (data not shown), but was found to be significantly
decreased in patients whose primary tumors were thicker
than 1 mm.
DISCUSSION
In this evaluation of a new international registry of
patients with primary PM, AJCC stage of disease, thick-
ness, and ulceration were found to be predictive of OS,
similar to adult melanoma. However, children with pri-
mary lesions measuring > 1 mm in thickness and those
with stage II or III disease had similar favorable survival
outcomes. Despite the presence of high-risk features and
an advanced stage of disease, children aged  10 years
were not found to have worse survival outcomes com-
pared with their adolescent counterparts aged> 10 years.
Lange et al published an analysis of PM from the
National Cancer Data Base (as well as a comparison group
aged 20 years-24 years).8,19 Several findings from the cur-
rent study corroborate those from the analysis by Lange
et al. Our results corroborated a higher frequency of inva-
sive melanoma in adolescents aged > 10 years versus chil-
dren aged  10 years. We confirmed a preponderance of
PM with female sex overall, noting PM to be more fre-
quent among males in the younger age group, whereas it
was more frequent among females in the older age group.8
Furthermore, younger patients were more likely to have
higher-stage disease at the time of diagnosis. In contrast to
the findings of Lange et al, the results of the current analy-
sis did not demonstrate decreased survival rates in patients
aged  10 years. In fact, we found a trend toward
improved survival in younger patients. We propose that,
with increased numbers of patients, this survival advant-
age could be significant.
Although Lange et al found that primary tumor
thickness was not related to survival outcomes in pediatric
patients,8 we found thickness to be a significant predictor
of survival. The effects of thickness on OS indicate a
breakpoint at 1 mm, with worse outcomes for patients
with lesions measuring > 1 mm. It is interesting to note
that Lange et al used a cutoff value of 1.5 mm, which is
similar to the pre-2002 AJCC staging system. The current
study data suggest the breakpoint of 1 mm is now










Observation 121 (36.6%) 2 (8.7%) 107 (37.0%) 12 (63.2%)
No SLNB, LND1 30 (9.1%) 1 (4.4%) 27 (9.3%) 2 (10.5%)
SLNB- 126 (38.1%) 11 (47.8%) 112 (38.8%) 3 (15.8%)
SLNB1, no LND 5 (1.5%) 0 (0.00%) 4 (1.4%) 1 (5.3%)
SLNB1, LND- 31 (9.4%) 5 (21.7%) 25 (8.7%) 1 (5.3%)
SLNB1, LND1 18 (5.4%) 4 (17.4%) 14 (4.8%) 0 (0.0%)
AJCC stage I 174 (53.7%) 6 (25.0) 153 (56.6%) 15 (75.0%)
II 67 (20.7%) 7 (29.2) 58 (20.7%) 2 (10.0%)
III 75 (23.2%) 10 (41.7%) 62 (22.1%) 3 (15.0%)
IV 8 (2.5%) 1 (4.2) 7 (2.5%) 0
P 5 .0054
Abbreviations: 1, positive; -, negative; AJCC, American Joint Committee on Cancer; LND, lymph node dissection, PM, pediatric melanoma; SLNB, sentinel
lymph node biopsy.
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appropriate and consistent with the AJCC staging system
after publication of the sixth edition. Although the effect
of thickness may not be completely linear in relation to
survival, the explanation for this is unclear. In general,
patients in the current study aged < 10 years had thicker
melanomas but, irrespective of their stage of disease at the
time of presentation, their OS was 100%. The effect of
thickness on OS appears to be driven by events in individ-
uals aged 10 years to 20 years, in whom diminished prog-
nosis was observed with thicker primary tumors. Further
analysis of the effects of thickness as well as the association
between puberty and melanoma behavior and prognosis
will be important in the future.
Stage and ulceration were found to be highly signifi-
cant predictors of OS among patients with PM. Among
those with stage II and III disease, outcome appears to be
driven by thickness and ulceration. However, the presence
of mitotic activity in the primary tumor did not correlate
Figure 1. Relation between overall survival and (Top) thickness
and (Middle) ulceration are shown for patients with invasive pri-
mary pediatric melanoma. (Bottom) Stage of disease was found
to be highly predictive of overall survival in these patients.
TABLE 4. Overall Survival in Pediatric Patients
With Invasive Melanoma
Factor Dead/No. 5-Years OS, % 10-Year OS, %
Overall 31/365 88.9 80.6
Age, y (P 5 .1473, log-rank test)
5 0/6 100.0 100.0
>5 to 10 0/19 100.0 100.0
>10, to 15 11/98 81.4 69.7
>15 to 20 20/222 88.9 79.5
>20 to 21 0/20 100.0 100.0
Sex (P 5 .9568, log-rank test)
Female 16/210 89.2 80.8
Male 15/155 80.4 80.4
Thickness, mm (P 5 .0077, log-rank test)
0-1.0 2/147 97.0 97.0
1.01-2.0 9/84 87.2 70.1
2.01-4.0 6/71 84.1 77.6
>4.0 4/25 80.1 80.1
Ulceration (P 5 .0022, log-rank test)
No 12/258 91.6 86.7
Yes 6/35 74.1 59.3
Unknown 3/34 91.9 76.6
Mitoses (P 5 .1637, log-rank test)
No 6/122 91.6 88.3
Yes 9/112 83.4 76.9
Unknown 16/131 90.2 77.6
Lymph node status (P 5 .0170, log-rank test)
Observation 9/121 90.8 84.6
No SLNB, LND1 9/30 63.1 63.1
SLNB- 3/126 97.8 80.7
SLNB1, no LND 0/5 100.0 NA
SLNB1, LND- 2/31 76.0 NA
SLNB1, LND1 1/18 88.9 NA
Stage (AJCC 6th edition) (P<.0001, log-rank test)
I 3/174 96.7 94.1
II 6/67 88.0 79.6
III 7/75 84.2 77.1
IV 4/8 40.0 NA
Abbreviations: 1, positive; -, negative; AJCC, American Joint Committee
on Cancer; LND, lymph node dissection; NA, not applicable; OS, overall
survival; SLNB, sentinel lymph node biopsy.
Original Article
4016 Cancer November 15, 2013
with significant differences in survival. This lack of corre-
lation may be related to the heterogeneous data from the
12 participating centers, in addition to a lack of standardi-
zation among pathologists for this factor before the
formalization of mitotic rate assessment in the seventh
edition of the AJCC staging manual. Central pathology
review would enhance the precision of this prognostic fac-
tor and is planned in the future when funds are available.
Among the goals of the current study was the evalua-
tion of the relationship between SLNB status and out-
come, given prior reports of elevated percentages of
positive SLNB results among younger patients with PM.
The number of patients with SLN involvement is too
small to reliably evaluate its impact on survival (there were
only 3 deaths reported in 54 patients with SLN-positive
PM). However, a positive lymph node dissection in the
absence of SLNB was found to be correlated with poorer
OS. This may reflect an earlier cohort of patients with
worse outcomes. It is unclear from the medical records
what percentage of patients underwent an elective lymph
node dissection versus the percentage with clinically appa-
rent disease. Patients with a negative SLNB had survival
rates similar to those who were only observed (without
undergoing SLNB or lymph node dissection). Despite rel-
atively high rates of lymph node metastasis among chil-
dren and adolescents with melanoma, the negative
prognostic impact of lymph node metastases on survival
appears to be less among children aged  10 years. How-
ever, we state this with caution while awaiting further
data, because the overall correlation of lymph node metas-
tases with adverse outcomes still predominates.
When evaluating cases of a relatively rare tumor over
a long period of time, one often encounters changes in
pathologic and surgical standards. For example, over the
course of the registry time frame, there were marked
changes in surgical techniques (including the introduction
of SLNB), changes in routine pathologic assessment
(introduction of the measurement of Breslow depth, Clark
level, ulceration, and mitoses), and increased focus on early
detection. It is possible that pathologic drift occurred over
this time frame. In the future, we propose to institute a
centralized review of the registry, which will allow us to
determine whether pathologic drift has occurred26 and to
impose a consistent pathologic scaling system, if necessary,
to correct for it. Furthermore, with increased recruitment
of study sites and prospective enrollment of subjects, we
intend to increase the number of cases and enable greater
homogeneity. In the current analysis, the sixth edition of
the AJCC staging system was used and applied to all mela-
nomas entered into the registry, which, in part, controls
for or dampens pathologic drift. We have to accept that we
cannot control for variations in the histological readings of
these melanomas by individual dermatopathologists; how-
ever, this registry portrays a true cross-section from reliable
institutions. Therefore, even without central pathology
review, the current study is important in that we believe it
represents realistic patient outcomes based on the evalua-
tion and treatment of patients with PM by high-quality
institutions.
Our original intention was to include PAMN data
in the registry. Although we identified > 208 PAMNs in
the database, the follow-up data on these lesions were
poor, and we were unable to evaluate any of the survival
outcomes for these patients. Because our database was
locked, several of the individual institutions have further
refined their institutional data and collected prospective
data. The PAMN data currently are being evaluated for a
separate publication that addresses the challenges of fol-
lowing such entities outside of cancer registries and the
benefits of centralized pathology review for analyzing such
lesions, for which follow-up and further analyses are
essential. In some cases, lesions originally identified as
PAMNs are found to be PM when they are followed for
sufficient time periods.4 Given the challenges in distin-
guishing PAMNs from PM histologically, we plan to
increase the number of PAMN cases and the length of
follow-up, and institute central pathology review as well
as investigate markers of metastatic potential in PAMNs.
We believe this registry provides a new platform for
the evaluation and collection of prospective as well as retro-
spective data to enhance the understanding of the molecu-
lar differences between these lesions in adults and in
children. Critical to this effort would be prospective tissue
collection of PMs and PAMNs to ascertain their molecular
characteristics and the molecular basis of any differences
from nominally similar tumors in adults. Recent studies
have evaluated molecular factors affecting the behavior of
melanoma in different age groups. Differences have been
found in microRNA expression for cell cycle, inflamma-
tion, and other pathways in melanomas based on age.2
Cutaneous melanoma in children and adolescents demon-
strates gain of KIT, whereas BRAFmutations occur at a fre-
quency similar to that noted in adults.27 Evaluation of
tissue samples in our registry would allow us to define fur-
ther the biologic behavior of PMs in comparison with adult
melanoma. Given recent data suggesting a potential bio-
logic sex difference in melanoma behavior,28,29 we would
also like to measure the impact of puberty more precisely
by determining Tanner stage; age at menarche; and, possi-
bly, progesterone, testosterone, and estrogen status. To
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improve our understanding of melanoma biology and
behavior in young adults and to provide accurate compari-
sons, we propose the inclusion of a cohort of adults aged 20
years to 29 years in future registry work.
Conclusions
To the best of our knowledge, this is the first summary of
a new international effort to define the biology and out-
comes of a PM registry and it demonstrates that whereas
children aged  10 years with invasive melanoma present
with more advanced disease, they also demonstrate a trend
toward increased survival compared with older cohorts.
Furthermore, we confirm that stage, thickness, ulceration,
and lymph node status are significant predictors of OS
among patients with PM. We anticipate that refinement
of the international database, establishment of central pa-
thology review, and increased institutional participation
will better define the behavior of PM and improve our
ability to care for patients with this disease. Future work is
planned to improve the data collection, add prospective
data entry for PAMNs, and potentially expand data col-
lection into the young adult population.
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